AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05097001 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DBS programming
Description: DBS readjustment based on COMPUTER or CLINICAL program
Study NCT05035316 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: acetylsalicylic acid
Description: Oral tablet: acetylsalicylic acid,150 mg, 1 tablet/day
Study NCT05035316 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Calcium
Description: Oral tablet: calcium, 1 tablet/day
Study NCT06078384 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 25 mg/ml
Description: Pembrolizumab drug product is a sterile-filtered liquid and is aseptically filled into single-use vials.~The vials contain 4 mL of sterile solution for IV infusion.
Study NCT06078384 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel injection
Description: Injectable solution for IV administration. Dose of 80 mg/m² weekly.
Study NCT05204381 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Theta-frequency near-zero phase lag stimulation
Description: Rhythmic transcranial magnetic stimulation (TMS) is delivered to both frontal and parietal cortex in theta-frequency (approximately 6 Hz) with a near-zero phase lag.
Study NCT05204381 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Theta-frequency anti-synchrony stimulation
Description: Rhythmic transcranial magnetic stimulation (TMS) is delivered to both frontal and parietal cortex in theta-frequency (approximately 6 Hz) with a 180 degree phase offset, anti-synchrony.
Study NCT05204381 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Arrhythmic near-zero phase lag stimulation
Description: Rhythmic transcranial magnetic stimulation (TMS) is delivered to both frontal and parietal cortex in an arrhythmic pattern with a near-zero phase lag matched in duration to the rhythmic stimulation for that session.
Study NCT05204381 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Arrhythmic independent stimulation
Description: Rhythmic transcranial magnetic stimulation (TMS) is delivered to both frontal and parietal cortex in different independent arrhythmic patterns matched in duration to the rhythmic stimulation for that session.
Study NCT06171763 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telemedicine
Description: The telehomecare solution involves an early discharge with continued home monitoring through the use of telemedicine utilizing an user-friendly mobile. Additionally, there were a clinical reassessment in person 72 hours after discharge to evaluate the outcomes and results of the intervention.
Study NCT05130177 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zimberelimab
Description: Zimberelimab is a fully human immunoglobulin G4 (hIgG4) monoclonal antibody (mAb) that targets the human programmed cell death-1 (PD-1) immune checkpoint.
Study NCT05130177 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Domvanalimab
Description: Domvanalimab is a humanized immunoglobulin G1 (IgG1) mAb that targets immune checkpoint TIGIT.
Study NCT04648631 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: antibiofilm surfactant wound gel (ABWG)
Description: ABWG is a hydro-gel applied topically using a tongue depressor
Study NCT05288075 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indacaterol/glycopyrronium
Description: In each period, subjects receive single dose of indacaterol/glycopyrronium consisting of 2 inhaled doses via Easyhaler or 2 capsules inhaled via Ultibro Breezhaler.~In addition to study treatments, activated charcoal will be administered on each study period before and after study drug administration.
Study NCT05288075 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Indacaterol/glycopyrronium
Description: In each period, subjects receive single dose of indacaterol/glycopyrronium consisting of 2 inhaled doses via Easyhaler or 2 capsules inhaled via Ultibro Breezhaler.~In addition to study treatments, activated charcoal will be administered on each study period before and after study drug administration.
Study NCT05204381 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Alpha-frequency near-zero phase lag stimulation
Description: Rhythmic transcranial magnetic stimulation (TMS) is delivered to both frontal and parietal cortex in alpha-frequency (approximately 10 Hz) with a near-zero phase lag.
Study NCT05204381 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Alpha-frequency anti-synchrony stimulation
Description: Rhythmic transcranial magnetic stimulation (TMS) is delivered to both frontal and parietal cortex in alpha-frequency (approximately 10 Hz) with a 180 degree phase offset, anti-synchrony.
Study NCT05359796 — intervention group
Intervention type: BIOLOGICAL
Intervention: Chronic hyperglycemia
Description: For each follow-up, the glycated albumin(GA) reflecting glycemic control of the past 2-3 weeks, the glycated hemoglobin(HbA1c) reflecting glycemic control of the past 2-3 months, and the advanced glycation end products(AGEs) will be measured.
Study NCT05359796 — intervention group
Intervention type: BIOLOGICAL
Intervention: Residual islet function
Description: For each follow-up, fasting and stimulated C-peptide levels will be measured.
Study NCT05359796 — intervention group
Intervention type: GENETIC
Intervention: Genetic variation
Description: Genetic variations of interest will be detected with the blood sample collected at baseline.
Study NCT05359796 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: Dietary constitutes
Description: For each follow-up, the dietary constitutes for the past 3 days will be recorded.
Study NCT05359796 — intervention group
Intervention type: GENETIC
Intervention: Microbiome composition and function
Description: For each follow-up, the fecal and oral samples will be collected for measurement.
Study NCT05359796 — intervention group
Intervention type: BIOLOGICAL
Intervention: Metabolome composition
Description: For each follow-up, the serum and urine samples will be collected for measurement.
Study NCT05359796 — intervention group
Intervention type: BIOLOGICAL
Intervention: Composition of peripheral blood immune cells
Description: For each follow-up, the peripheral blood mononuclear cells will be collected for measurement.
Study NCT04231279 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: synthetic human secretin
Description: Secretin is a gastrointestinal peptide hormone, indicated for the stimulation of: pancreatic secretions, including bicarbonate, to aid in the diagnosis of pancreatic exocrine dysfunction.
Study NCT04231279 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: synthetic human secretin
Description: Secretin is a gastrointestinal peptide hormone, indicated for the stimulation of: pancreatic secretions, including bicarbonate, to aid in the diagnosis of pancreatic exocrine dysfunction.
Study NCT05793996 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferinject
Description: The calculation of the dose of iron carboxymaltosate (Ferinject ® preparation) for the purpose of correction of iron will be carried out on the basis of the following step-by-step approach: determination of individual iron needs, calculation and administration of iron dose, assessment of the saturation of the patient's body with iron 6 weeks after infusion.
Study NCT05793996 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Diet therapy
Description: Patients will receive diet therapy to correct latent iron deficiency
Study NCT03650374 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care Rehabilitation
Description: Knee flexion and extension strength training exercises for the contralateral (non-operative) lower extremity in addition to standard of care postoperative rehabilitation.
Study NCT03650374 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental Strength Training
Description: Will be performed with moderate resistance and will require moderate effort. Exercises will include unilateral leg presses, lunges, step ups, and step downs. These exercises are performed as standard of care but are not typically introduced into the physical therapy regimen until 10-12 weeks postoperatively. In the experimental group, these exercises will be introduced starting with the first postoperative physical therapy session, but only for the contralateral (non-operative) leg.
Study NCT05289141 — intervention group
Intervention type: DEVICE
Intervention: Use of high flow nasal oxygen therapy
Description: Use of high flow nasal oxygen therapy during secondary transport by emergency medical service 83 (SAMU 83).
Study NCT05289141 — intervention group
Intervention type: DEVICE
Intervention: Use of other non-invasive ventilation or high concentration oxygen masks
Description: Use of other non-invasive ventilation or high concentration oxygen masks during secondary transport by emergency medical service 83 (SAMU 83).
Study NCT05116319 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: point-of-care HbA1c
Description: The Afinion2™ (Abbott, Oslo, Norway), will be used for the current study as it is recently validated. According to American Diabetes Association (ADA), pre-diabetes (pre-DM) is diagnosed if HbA1c is 5.7-6.4% and diabetes (DM) is diagnosed if HbA1c is ≥6.5%
Study NCT05872542 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Silver Diamine Fluoride (SDF)
Description: Proper isolation of the operating field and removal of gross debris. Minimize contact with the gingiva and mucus membrane. Gentle dryness with compressed air. Dip and dab micro brush on the side of the dapper dish. Apply SDF to the affected surface (one drop/ appointment). Gentle dryness with compressed air for one minute. Remove excess SDF with gauze or cotton pellets. Continue to isolate the site for up to three minutes.
Study NCT05872542 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Glass Ionomer Restoration (GI)
Description: Application of GI restoration necessitates removal of carious tissue using round bur rotating on low-speed contra and excavation of infected carious dentin. Followed by restoring the prepared cavity with glass ionomer restoration according to the manufacturer's instructions. The restoration will be checked for any high spots and occlusal interference (if any) will be corrected.
Study NCT05872542 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sodium fluoride varnish with nano-sliver particles (NaF-AgNP)
Description: Proper isolation of the operating field and removal of gross debris. Minimize contact with the gingiva and mucus membrane. Gentle dryness with compressed air. Dip and dab micro brush on the side of the dapper dish. Apply NaF-AGNP to the affected surface (one drop/ appointment). Gentle dryness with compressed air for one minute. Continue to isolate the site for up to three minutes.
Study NCT06198712 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etavopivat
Description: Participants will receive oral tablets of etavopivat once daily.
Study NCT05477576 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RYZ101
Description: RP3D as determined in Phase 1b
Study NCT05477576 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RYZ101
Description: RP3D as determined in Phase 1b
Study NCT05477576 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Everolimus
Description: Everolimus
Study NCT05477576 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sunitinib
Description: Sunitinib
Study NCT05477576 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Octreotide
Description: High-dose octreotide
Study NCT05477576 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lanreotide
Description: Lanreotide
Study NCT04983264 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GBT021601
Description: Tablets and capsules which contain GBT021601 drug substance
Study NCT05736068 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non-surgical treatment
Description: If allocated to non-surgical group, cast optimization in the outpatient clinic may be necessary if the cast from the emergency room is considered insufficient.
Study NCT05736068 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical treatment
Description: Closed reduction with or without fixation
Study NCT06281028 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: SOLACEA-H/HYDROLINK-NVU
Description: Patients will receive 6 sessions of washout treatment, followed by a gradual tapering phase (4 sessions maximum) during which the anticoagulant will be reduced from the normal dose to the minimum effective dose (which may be zero) and maintained for a minimum of 2 sessions on the SOLACEA-H, followed by 6 washout sessions, then again a gradual reduction phase (4 sessions maximum) during which the anticoagulant will be reduced from the normal dose to the minimum effective dose (which may be zero) and maintained for a minimum of 2 sessions on the HYDROLINK-NVU.
Study NCT06281028 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: HYDROLINK-NVU/SOLACEA-H
Description: Patients will receive 6 sessions of washout treatment, followed by a gradual tapering phase (4 sessions maximum) during which the anticoagulant will be reduced from the normal dose to the minimum effective dose (which may be zero) and maintained for a minimum of 2 sessions on the HYDROLINK-NVU, followed by 6 washout sessions, then again a gradual reduction phase (4 sessions maximum) during which the anticoagulant will be reduced from the normal dose to the minimum effective dose (which may be zero) and maintained for a minimum of 2 sessions on the SOLACEA-H.
Study NCT05844514 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Breath test
Description: Patients must be fasted for a minimum of four hours prior to breath sample collection. For patients undergoing colonoscopy or surgery, breath samples must be obtained prior to patients receiving bowel preparation in either outpatient clinic or pre-assessment clinic.
Study NCT04719390 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text Message
Description: Maternal-Focused Message: When randomized to receive a maternal-focused message, participants will receive a message that is focused on the transition to motherhood and the joys and challenges of caring for a newborn.~Drinking-Focused Message:~When randomized to receive a drinking-focused message, participants will receive a message that is focused on reducing alcohol use.~All messages of both types are designed to map onto behavior change techniques that are empirically supported for alcohol use.
Study NCT05426629 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Venus Glow
Description: The Venus Glow hydradermabrasion device is a class 1 device trimodality dermal system consisting of vacuum, 360 degrees rotating tip and two jet streams of saline.~Adjustable vacuum deep cleanses the pores by pulling up daily dirt and debris, dry and dead skin cells, and excess sebum from the stratum corneum. It helps increase the microcirculation.~The 360-degree rotation helps in spreading the saline evenly, which is expelled from two ultra-fine jet streams. This micro massaging helps in faster release of nutrients from the skin. The jet stream is smaller than the average pore size measuring 50- 70 microns each, enabling the jet stream to deep clean each pore.
Study NCT05560529 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DBT
Description: Applying DBT modules in group format over 20 weeks
Study NCT05560529 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TAU
Description: Giving TAU (usual pharmacotherapy in BED) over 20 weeks
Study NCT05560529 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Plasma Ghrelin
Description: Measuring fasting plasma ghrelin pre and post treatment in both arms
Study NCT05560529 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Plasma Ghrelin
Description: Measuring fasting plasma ghrelin pre and post treatment in both arms
Study NCT06522308 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Hepatobiliary ultrasound
Description: The presence of cholelithiasis in patients with umbilical hernia is detected by hepatobiliary ultrasound
Study NCT06522308 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Umbilical region superficial tissue ultrasound
Description: The presence of umbilical hernia in patients with cholelithiasis is detected by ultrasound of the superficial tissue of the umbilical region.
Study NCT05669755 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cagrilintide
Description: Participants will receive 2.4 mg cagrilintide s.c. once-weekly after a dose escalation period of 16 weeks for 219 weeks.
Study NCT05669755 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide
Description: Participants will receive 2.4 mg semaglutide s.c. once-weekly after a dose escalation period of 16 weeks for 219 weeks.
Study NCT05669755 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive placebo matched to cagrilintide and placebo matched to semaglutide subcutaneously.
Study NCT06553768 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maralixibat
Description: Maralixibat will be provided as an oral solution along with 0.5-, 1.0-, and 3.0-mL sized dosing dispensers. During the double-blind dose escalation period (4 weeks), the study drug (maralixibat) will be administered once daily for 1 week and then twice daily (BID; morning and evening). During the double-blind stable dosing period (16 weeks), participants will be treated with 300 μg/kg BID or the maximum tolerated dose (determined during the double-blind dose-escalation period) of maralixibat. During the open-label dose escalation period (4 weeks), all participants will receive maralixibat treatment once daily for 1 week and then twice daily (BID; morning and evening). During the open-label stable dosing period (at least 16 weeks), participants will be treated with 300 μg/kg BID or the maximum tolerated dose (determined during the open-label dose-escalation period) of maralixibat.
Study NCT06553768 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matched to maralixibat will be provided as an oral solution along with 0.5-, 1.0-, and 3.0-mL sized dosing dispensers. During the double-blind dose escalation period (4 weeks), study drug will be administered once daily for 1 week and then twice daily (BID; morning and evening). During the double-blind stable dosing period (16 weeks), participants will be treated with 300 μg/kg BID or the maximum tolerated dose (determined during the double-blind dose-escalation period) of study drug. During the open-label dose escalation period (4 weeks), all participants will receive maralixibat treatment once daily for 1 week and then twice daily (BID; morning and evening). During the open-label stable dosing period (16 weeks), participants will be treated with 300 μg/kg BID or the maximum tolerated dose (determined during the open-label dose-escalation period) of maralixibat.
Study NCT05580562 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dordaviprone (ONC201)
Description: Participants ≥ 52.5 kg will receive 625 mg of ONC201 (5 × 125-mg capsules) dosing days; participants \< 52.5 kg will receive a dose (and corresponding number of capsules) scaled by body weight and rounded to 125-mg increments.
Study NCT05580562 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dordaviprone (ONC201) + Placebo
Description: Participants ≥ 52.5 kg will receive 625 mg of ONC201 (5 × 125-mg capsules) or matching placebo on dosing days; participants \< 52.5 kg will receive a dose (and corresponding number of capsules) scaled by body weight and rounded to 125-mg increments
Study NCT05580562 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive placebo (same number of capsules as the ONC201 dose) on dosing days
Study NCT05440929 — intervention group
Intervention type: BEHAVIORAL
Intervention: Clinician Qualitative Interview
Description: Interviews will be conducted by experienced qualitative researchers from the UNC Connected Health for Applications \& Interventions (CHAI) Core. The interview will be conducted over the phone or secure videoconferencing. The interview will be conducted in a semi-structured fashion using an interview guide. However, because the purpose of this semi-structured qualitative interview study is to determine which themes participants identify as important, the exact content of each interview will differ, and the interview guide will be modified as additional interviews are conducted. Interviews will be audio recorded with concurrent notetaking by the interviewer.
Study NCT04961528 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid 500 MG
Description: Jet nebulization (a device connected by tubing to compressed air or oxygen to flow at high velocity through a liquid medicine to turn it into an aerosol, which is then inhaled by the patient).~The nebulization lasts 10 minutes. Posology: 500 mg x 3/day (= 500 mg / 8 hours) Treatments duration: 3 days
Study NCT04961528 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Terlipressin
Description: Jet nebulization (a device connected by tubing to compressed air or oxygen to flow at high velocity through a liquid medicine to turn it into an aerosol, which is then inhaled by the patient).~The nebulization lasts 10 minutes. Posology: 1 mg x 3/day (= 1 mg / 8 hours) Treatments duration: 3 days
Study NCT04961528 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Jet nebulization (a device connected by tubing to compressed air or oxygen to flow at high velocity through a liquid medicine to turn it into an aerosol, which is then inhaled by the patient).~The nebulization lasts 10 minutes. Posology: 5ml x 3/day (= 5 ml / 8 hours) Treatments duration: 3 days.
Study NCT05643599 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: Mad Honey
Description: mad honey (80 mg/kg); (n:6)
Study NCT05643599 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: Normal Honey
Description: normal honey (80 mg/kg),(n:6)
Study NCT05643599 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: Control
Description: Control
Study NCT04883775 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MVT-2163
Description: MVT-2163 is administered intravenously as a PET imaging agent.